Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyMolina Ravicti Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C7041-A

    Chronic Hyperammonemia: Ravicti (Glycerol Phenylbutyrate)

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C7041-A alerts

    Get alerted when Policy C7041-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and continued coverage of oral Ravicti for chronic hyperammonemia caused by a qualifying urea cycle disorder, subject to diagnostic confirmation, required prior therapies, specialist involvement, and evidence of treatment response and adherence.

    Policy Summary
    PayerMolina Healthcare
    PolicyChronic Hyperammonemia: Ravicti (Glycerol Phenylbutyrate)
    Policy CodePolicy C7041-A
    Change TypeNo material change
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit current fasting plasma ammonia results within 60 days for reauthorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3 monthsInitial authorization duration
    12 monthsContinuation authorization duration
    85%Minimum adherence threshold
    17.5 mL/dayMaximum quantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    15 days
    Required alternative-drug trial
    NonePolicy age restriction

    Coverage Criteria

    Initial Therapy Criteria

    Covered when all initial therapy criteria are met.

    Initial therapy

    • Documentation confirms chronic hyperammonemia due to a urea cycle disorder (UCD).
    • The diagnosis is confirmed by enzymatic, biochemical, and/or genetic testing.
    • The baseline plasma ammonia level obtained at diagnosis is documented for efficacy monitoring.
    • The prescriber attests that the member does not have acute hyperammonemia.
    • The condition has failed to be managed with dietary protein restriction and/or amino acid supplementation alone, including applicable essential amino acids, arginine, citrulline, or protein-free calorie supplements.
    • The member has a documented 15-day trial of sodium phenylbutyrate powder (Buphenyl), sodium phenylbutyrate tablets (Buphenyl), and Pheburane sodium phenylbutyrate pellets, with failure, ineffectiveness, contraindication, or serious side effects for each product.15 days for each required sodium phenylbutyrate product
    • Ravicti therapy will be used concomitantly with dietary protein restriction and, when appropriate, dietary supplements.
    • Ravicti is prescribed by, or in consultation with, a board-certified geneticist/metabolic specialist or a physician experienced in managing urea cycle disorders.

      When prescribed in consultation, submit consultation notes with the initial request.

    Continuation Therapy Criteria

    Continuation therapy is covered when all continuation criteria are met.

    Continuation therapy

    • The member demonstrates stabilization or improvement due to Ravicti therapy, evidenced by decreased fasting plasma ammonia levels indicative of efficacy.
    • A current plasma ammonia level is submitted.Obtained within 60 days of the request date

      Normal ranges and therapeutic target levels depend on the assay method used by the laboratory; use assay-specific ranges.

    • Adherence to therapy is at least 85% as verified by the prescriber or medication fill history, or adherence below 85% is due to surgery or treatment of an infection causing temporary discontinuation.At least 85% unless the allowed temporary interruption applies

    Ravicti is excluded for acute hyperammonemia, hypersensitivity to sodium phenylbutyrate or any component of the formulation, and N-acetylglutamate synthase (NAGS) deficiency, for which safety and efficacy have not been established. Other uses designated experimental or investigational are also excluded.

    Ravicti is not medically necessary for acute hyperammonemia or for uses outside the chronic management of a qualifying urea cycle disorder when the condition can be managed with dietary protein restriction and/or amino acid supplementation alone. Other uses are considered experimental or investigational under Molina’s Off-Label policy.

    Operational Requirements

    Current Plasma Ammonia for Continuation
    Required resultCurrent plasma ammonia level
    TimingObtained within 60 days of the request date
    Continuation useUsed to document stabilization or improvement due to Ravicti therapy, evidenced by decreased fasting plasma ammonia levels
    Medication Adherence
    Minimum adherenceAt least 85% of the time
    Temporary interruption exceptionAdherence below 85% is allowed when surgery or treatment of an infection causes temporary discontinuation
    Verification

    Provider Documentation and Authorization

    Prior Authorization

    Initial Prior Authorization — Required Documentation

    Submit the initial prior authorization request with documentation supporting chronic hyperammonemia due to a urea cycle disorder, confirmatory testing, baseline ammonia, required treatment history, and the prescriber attestations. Ravicti must be used with dietary protein restriction and, when clinically appropriate, amino acid or protein-free calorie supplementation.

    • Document the diagnosis of chronic hyperammonemia due to a urea cycle disorder.
    • Submit enzymatic, biochemical, and/or genetic testing confirming the diagnosis.
    • Submit the plasma ammonia level obtained at diagnosis for efficacy monitoring.
    • Prescriber attests that the member does not have acute hyperammonemia.
    • Document failure of dietary protein restriction and/or amino acid supplementation alone.
    • Document the required 15-day trials and outcomes for all specified sodium phenylbutyrate products.
    • Document that Ravicti will be used concomitantly with dietary protein restriction and, in some cases, dietary supplements.
    Prior Authorization

    Clinical Background

    Urea cycle disorders are inherited deficiencies of enzymes involved in converting nitrogen to urea, which can result in chronic hyperammonemia. Ravicti (glycerol phenylbutyrate) is an oral nitrogen-binding agent for chronic management of members with a urea cycle disorder who cannot be managed with dietary protein restriction and/or amino acid supplementation alone. It must be used with dietary protein restriction and, when appropriate, nutritional supplements such as essential amino acids, arginine, citrulline, or protein-free calorie supplements. Ravicti is not intended for acute hyperammonemia, when more rapidly acting interventions are required to reduce plasma ammonia levels.

    Key Definitions

    Urea Cycle Disorder (UCD)
    DefinitionInherited disorders caused by deficiency of an enzyme in the pathway that transforms nitrogen to urea
    Listed disorder typesOrnithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase, and N-acetylglutamate synthetase (NAGS) deficiencies
    Clinical resultUrea cycle disorders are associated with chronic hyperammonemia
    Ravicti (Glycerol Phenylbutyrate)
    MedicationRavicti (glycerol phenylbutyrate) is an oral nitrogen-binding liquid
    IndicationChronic management of patients with urea cycle disorders

    Ravicti Initial Authorization

    Ravicti Initial Authorization

    Initial Ravicti therapy requires all criteria below.

    Initial Ravicti authorization

    • Documentation confirms chronic hyperammonemia due to a urea cycle disorder (UCD).
    • The diagnosis is confirmed by enzymatic, biochemical, and/or genetic testing.
    • The baseline plasma ammonia level obtained at diagnosis is documented for efficacy monitoring.
    • The prescriber attests that the member does not have acute hyperammonemia.
    • The condition has failed to be managed with dietary protein restriction and/or amino acid supplementation alone, including applicable essential amino acids, arginine, citrulline, or protein-free calorie supplements.

    Ravicti Continuation

    Ravicti Continuation Criteria

    Continuation therapy requires all of the following.

    Ravicti continuation

    • The member demonstrates stabilization or improvement due to Ravicti therapy, evidenced by decreased fasting plasma ammonia levels indicative of efficacy.
    • A current plasma ammonia level is submitted within 60 days of the request date.Within 60 days of the request date

      Use the assay-specific normal ranges and therapeutic target ranges for plasma ammonia.

    • Adherence to Ravicti therapy is at least 85% as verified by the prescriber or medication fill history, or adherence below 85% is due to surgery or treatment of an infection causing temporary discontinuation.At least 85% unless the allowed temporary interruption applies

    Required Alternative Therapy

    StepRequired sodium phenylbutyrate productRequirement
    1Sodium phenylbutyrate powder (Buphenyl)Document a 15-day trial with failure or ineffectiveness, contraindication, or serious side effects before Ravicti coverage.
    1Sodium phenylbutyrate tablets (Buphenyl)Document a 15-day trial with failure or ineffectiveness, contraindication, or serious side effects before Ravicti coverage.
    1Pheburane (sodium phenylbutyrate pellets)Document a 15-day trial with failure or ineffectiveness, contraindication, or serious side effects before Ravicti coverage.

    Ravicti Quantity and Dosage Limits

    Ravicti Maximum Quantity Limit
    MedicationRavicti (glycerol phenylbutyrate)
    Maximum daily quantity17.5 mL per day
    Gram equivalent19 g per day
    Ravicti Recommended Dosage Range
    Recommended dosage range4.5 to 11.2 mL/m²/day
    Dose divisionAdministered in equally divided portions
    Daily frequencyThree times daily

    Site of Care and Benefit

    Billing Rule

    Bill under the pharmacy benefit

    Oral Ravicti is covered under the pharmacy benefit and is intended for patient self-administration.

    Policy Summary
    PayerMolina Healthcare
    PolicyChronic Hyperammonemia: Ravicti (Glycerol Phenylbutyrate)
    Policy CodePolicy C7041-A
    Change TypeNo material change
    Effective DateSeptember 24, 2026
    Next Review DateJuly 1, 2027
    Key ActionSubmit current fasting plasma ammonia results within 60 days for reauthorization.
    SourceLink
    On This Page
    Coverage CriteriaOperational RequirementsProvider Documentation and AuthorizationClinical BackgroundKey DefinitionsRavicti Initial AuthorizationRavicti ContinuationRequired Alternative TherapyRavicti Quantity and Dosage LimitsSite of Care and Benefit
    The prescriber attests to, or the clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity.
    Verified by the prescriber or the member’s medication fill history
    Alternative-Drug Trial
    Required trial period15 days for each required sodium phenylbutyrate product
    Required productsSodium phenylbutyrate powder (Buphenyl), sodium phenylbutyrate tablets (Buphenyl), and Pheburane sodium phenylbutyrate pellets
    Acceptable outcomeFailure or ineffectiveness, contraindication, or serious side effects

    Continuation Prior Authorization — Required Evidence

    For reauthorization, submit current clinical and laboratory evidence showing that the member continues to benefit from Ravicti and is receiving therapy as prescribed. The current plasma ammonia level must be obtained within 60 days of the request date.

    • Submit the current plasma ammonia level and laboratory-specific normal and therapeutic target ranges, as applicable.
    • Document stabilization or improvement, evidenced by decreased fasting plasma ammonia levels indicative of efficacy.
    • Document adherence of at least 85% by prescriber attestation or medication fill history, or explain adherence below 85% due to surgery or treatment of an infection causing temporary discontinuation.
    • Prescriber attests, or the clinical reviewer confirms, no intolerable adverse effects or drug toxicity.
    • Submit consultation notes with each reauthorization request when the prescriber is working in consultation with a specialist.
    Step Therapy

    Required Sodium Phenylbutyrate Step Therapy

    Ravicti is subject to sodium phenylbutyrate step therapy before initial approval. The member must have a documented 15-day trial of each required product with failure or ineffectiveness, a contraindication, or serious side effects.

    • Sodium phenylbutyrate powder (Buphenyl).
    • Sodium phenylbutyrate tablets (Buphenyl).
    • Pheburane (sodium phenylbutyrate pellets).
    Documentation Required

    Diagnostic Confirmation Required

    Confirm that the member has chronic hyperammonemia caused by a urea cycle disorder and submit documentation of diagnostic confirmation. Acceptable confirmation includes enzymatic, biochemical, and/or genetic testing.

    • Document the specific urea cycle disorder diagnosis.
    • Submit the relevant confirmatory test report or clinical documentation of enzymatic, biochemical, or genetic confirmation.
    Documentation Required

    Baseline Ammonia Level

    Submit the member’s plasma ammonia level obtained at the time of diagnosis. This baseline value is required for monitoring efficacy over the course of treatment.

    • Baseline plasma ammonia level at diagnosis is required with the initial request.
    Documentation Required

    Failure of Dietary Management

    Document that the member’s condition could not be managed with dietary protein restriction and/or amino acid supplementation alone. Ravicti remains medically appropriate only when used with dietary management and, in some cases, dietary supplements.

    • Document failure of dietary protein restriction alone and/or amino acid supplementation alone.
    • Relevant supplementation may include essential amino acids, arginine, citrulline, or protein-free calorie supplements.
    Documentation Required

    Required Alternative-Drug Trials

    Document the required trials of sodium phenylbutyrate products and the outcome of each trial. The record must identify whether each product failed or was ineffective, was contraindicated, or caused serious side effects.

    • Sodium phenylbutyrate powder (Buphenyl): document trial duration and outcome.
    • Sodium phenylbutyrate tablets (Buphenyl): document trial duration and outcome.
    • Pheburane sodium phenylbutyrate pellets: document trial duration and outcome.
    • Each required trial must be documented for at least 15 days unless a contraindication or serious side effect supports the exception.
    Documentation Required

    Continuation Laboratory Documentation

    Continuation requests must include current laboratory and clinical documentation demonstrating ongoing response to Ravicti. Submit evidence of ammonia improvement or stabilization and compliance with the continuation requirements.

    • Current plasma ammonia level must be within 60 days of the request date.
    • Document decreased fasting plasma ammonia levels or other evidence of stabilization or improvement attributable to Ravicti.
    • Include adherence documentation and any permitted explanation for temporary treatment interruption.

    Unsupported block type: documentation

    Denial Risk

    Failure to Meet Initial Authorization Criteria

    The initial request will be denied when the required diagnosis, testing, baseline ammonia, treatment history, attestations, or treatment plan is not documented. Initial approval also requires that the member does not have acute hyperammonemia and that all required criteria are met.

    • No documented chronic hyperammonemia due to a urea cycle disorder or no confirmatory enzymatic, biochemical, or genetic testing.
    • No baseline plasma ammonia level obtained at diagnosis.
    • No documentation of failure of dietary protein restriction and/or amino acid supplementation alone.
    • Failure to document the required 15-day trial and qualifying outcome for every required sodium phenylbutyrate product.
    • Prescriber does not attest that the member does not have acute hyperammonemia.
    • Ravicti is not planned for use with required dietary protein restriction and applicable supplementation.
    • Required specialist involvement or consultation documentation is absent when applicable.
    Denial Risk

    Failure to Meet Continuation Criteria

    Continuation will be denied when current evidence does not demonstrate ongoing benefit, required laboratory documentation is missing, adherence requirements are not met, or safety concerns preclude continued treatment.

    • Current plasma ammonia level is missing or was obtained more than 60 days before the request date.
    • No documented stabilization or improvement, including decreased fasting plasma ammonia levels indicative of efficacy.
    • Adherence is below 85% without the permitted explanation for surgery or infection-related temporary discontinuation.
    • Intolerable adverse effects or drug toxicity are present.
    • Required specialist consultation notes are not submitted when the prescription involves consultation.
    Denial Risk

    Excluded or Investigational Uses

    Ravicti is not covered under this policy for acute hyperammonemia or N-acetylglutamate synthase (NAGS) deficiency. Uses outside the covered chronic urea cycle disorder indication are considered experimental or investigational and follow Molina’s Off-Label policy.

    • Do not use Ravicti as treatment for acute hyperammonemia; more rapidly acting interventions are essential.
    • Safety and efficacy for NAGS deficiency have not been established.
    • Other uses of glycerol phenylbutyrate oral liquid are experimental/investigational under this policy.
    • Ravicti is contraindicated for hypersensitivity to sodium phenylbutyrate or any formulation component and for management of acute hyperammonemia.
    Use condition
    For patients who cannot be managed with dietary protein restriction and/or amino acid supplementation alone; use with dietary protein restriction and, in some cases, dietary supplements
    Fasting Plasma Ammonia Level
    DefinitionA plasma ammonia measurement obtained while fasting
    Treatment-response useUsed to assess efficacy and treatment response
    Continuation applicationDecreased fasting plasma ammonia levels are used as evidence of stabilization or improvement due to Ravicti therapy
  1. The member has a documented trial of all required sodium phenylbutyrate alternatives: sodium phenylbutyrate powder (Buphenyl), sodium phenylbutyrate tablets (Buphenyl), and Pheburane sodium phenylbutyrate pellets.15 days for each product
  2. Each required alternative was ineffective, contraindicated, or associated with serious side effects, or the member failed the trial.
  3. Ravicti therapy will be used concomitantly with dietary protein restriction and, when appropriate, dietary supplements.
  4. Ravicti is prescribed by, or in consultation with, a board-certified geneticist/metabolic specialist or a physician experienced in managing urea cycle disorders.

    When prescribed in consultation, consultation notes must be submitted with the initial request.

  5. The prescriber attests to, or the clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity.